Phytopharm completes the first stage of R&D accord with Unilever

16 April 2006

UK-based drug developer Phytopharm says it has completed the first stage of an R&D agreement with consumer products giant Unilever relating to the development of the Hoodia gordonii extract. Under the terms of the deal, which was initiated in 2004 (Marketletters passim), the two firms are collaborating on bringing weight-control products based on the extract to the marketplace. Unilever has committed L3.5 million ($6.1 million) to the second stage of the project.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight